Anesthesiology · 2026
Rapid Sequence Induction Practices and Outcomes in Abdominal Surgery Patients: A Multicenter Observational Cohort Study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marcus Sivan G, Mathis Michael, Bokoch Michael P, Freundlich Robert, Chen David, Chen Lee-Lynn, Legrand Matthieu, MPOG Collaborators
Аннотация
BACKGROUND: Rapid sequence induction (RSI) is commonly performed in the operating room to quickly secure the airway and minimize aspiration risk, especially in patients undergoing abdominal surgery. Current practice patterns of medications and RSI techniques used by anesthesiologists are not well described.
METHODS: This observational cohort study utilized the Multicenter Perioperative Outcomes Group database to evaluate RSI practices on adult patients undergoing abdominal surgery from 2015 to 2022. The primary aim was to describe modern RSI practices. The authors evaluated peri-induction medication use and intubation techniques. The authors hypothesized that over time, rocuronium would become the most utilized agent. Additionally, the authors investigated how the choice of neuromuscular blocking agent affected outcomes using mixed-effects models and targeted maximum likelihood estimation. The primary endpoint was 30-day mortality. Secondary endpoints included postinduction hypoxia, pulmonary complications, and acute kidney injury (AKI).
RESULTS: Across 13 institutions and 82,772 cases, 9,352 (11.3%) had a documented RSI. The most common neuromuscular blocking agent was succinylcholine (70.5%). However, the use of succinylcholine significantly decreased during the study period (85.4% of RSI cases in 2015, 37.3% in 2022; P < 0.0001), replaced by rocuronium. Patients usually received coadministration of multiple sedatives. Video laryngoscopy was more frequently used (16.2% of RSI vs. 8.0% of non-RSI cases; P < 0.0001). Rocuronium was not associated with a different risk of mortality (relative risk, 0.85; 95% CI, 0.67 to 1.09), hypoxia (relative risk, 1.04; 95% CI, 0.61 to 1.77), pulmonary complications (relative risk, 0.93; 95% CI, 0.81 to 1.06), or AKI (relative risk, 1.05; 95% CI, 0.84 to 1.31) as compared to succinylcholine.
CONCLUSIONS: Across institutions in the United States, rocuronium has been increasingly used for RSI, eventually overtaking succinylcholine. Rocuronium use was not associated with a different risk of mortality, hypoxia, pulmonary complications, or AKI.
METHODS: This observational cohort study utilized the Multicenter Perioperative Outcomes Group database to evaluate RSI practices on adult patients undergoing abdominal surgery from 2015 to 2022. The primary aim was to describe modern RSI practices. The authors evaluated peri-induction medication use and intubation techniques. The authors hypothesized that over time, rocuronium would become the most utilized agent. Additionally, the authors investigated how the choice of neuromuscular blocking agent affected outcomes using mixed-effects models and targeted maximum likelihood estimation. The primary endpoint was 30-day mortality. Secondary endpoints included postinduction hypoxia, pulmonary complications, and acute kidney injury (AKI).
RESULTS: Across 13 institutions and 82,772 cases, 9,352 (11.3%) had a documented RSI. The most common neuromuscular blocking agent was succinylcholine (70.5%). However, the use of succinylcholine significantly decreased during the study period (85.4% of RSI cases in 2015, 37.3% in 2022; P < 0.0001), replaced by rocuronium. Patients usually received coadministration of multiple sedatives. Video laryngoscopy was more frequently used (16.2% of RSI vs. 8.0% of non-RSI cases; P < 0.0001). Rocuronium was not associated with a different risk of mortality (relative risk, 0.85; 95% CI, 0.67 to 1.09), hypoxia (relative risk, 1.04; 95% CI, 0.61 to 1.77), pulmonary complications (relative risk, 0.93; 95% CI, 0.81 to 1.06), or AKI (relative risk, 1.05; 95% CI, 0.84 to 1.31) as compared to succinylcholine.
CONCLUSIONS: Across institutions in the United States, rocuronium has been increasingly used for RSI, eventually overtaking succinylcholine. Rocuronium use was not associated with a different risk of mortality, hypoxia, pulmonary complications, or AKI.